Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Jeito Capital is a global investment firm based in Paris, founded in September 2021 by Dr. Rafaèle Tordjman, a hematologist with over 20 years of experience in life sciences. The firm specializes in financing and accelerating medical innovations that significantly benefit patients. Jeito has successfully raised €534 million (approximately $630 million) for its inaugural fund dedicated to biopharmaceuticals. This substantial capital allows Jeito to support a diverse range of innovative medical companies, primarily in Europe and the United States. The firm has quickly established a reputation for its strategic investments in the healthcare sector, focusing on therapeutic areas that are critical for patient care.
Jeito Capital invests primarily in biopharmaceuticals and innovative medical companies, with a keen focus on therapeutic areas such as immuno-oncology, ophthalmology, cardiology, severe respiratory diseases, and fibrosis. The firm supports companies at various stages of development, from clinical trials to market access, ensuring that they have the necessary resources to bring their innovations to market. Jeito's investment strategy emphasizes collaboration with founders and management teams to drive growth and success. The firm typically invests in early to growth stages, including Pre Seed, Seed, Series A, Series B, and Series C rounds, making it a versatile partner for startups looking to scale their operations in the biopharma sector.
Jeito Capital's portfolio features notable companies that are making significant strides in the biopharmaceutical industry. One of its standout investments is Neogene Therapeutics, which was acquired by AstraZeneca in January 2023, highlighting the firm's ability to identify and support high-potential companies. Other key portfolio companies include SparingVision, known for developing gene therapies for retinal degeneration, and Pulmocide, which focuses on innovative treatments for severe respiratory diseases. Additionally, Jeito has invested in Alentis Therapeutics, Quell Therapeutics, and NMD Pharma, each contributing to advancements in their respective therapeutic areas. The firm's diverse portfolio underscores its commitment to fostering innovation in healthcare and improving patient outcomes.
Dr. Rafaèle Tordjman - Founder and Managing Partner. Dr. Tordjman is a hematologist with over 20 years of experience in life sciences, leading Jeito's strategic vision and investment decisions.
To pitch Jeito Capital, founders should visit their website at jeito.life or email careers@jeito.life. They prefer well-structured pitches that clearly articulate the innovation and potential impact of the proposed solutions. Warm introductions are beneficial but not mandatory.
Jeito Capital invests in various stages, including Pre Seed, Seed, Series A, Series B, and Series C. This broad range allows them to support companies at different points in their development journey.
Founders can pitch Jeito Capital by visiting their website at jeito.life or by emailing them directly at careers@jeito.life. They welcome pitches that clearly outline the innovation and potential impact of the proposed medical solutions.
Jeito Capital primarily focuses on the biopharmaceutical sector, investing in innovative medical companies that operate in therapeutic areas such as immuno-oncology, ophthalmology, cardiology, severe respiratory diseases, and fibrosis.
While specific check sizes are not disclosed, Jeito Capital's fund size of approximately $630 million indicates that they are capable of making significant investments across various funding rounds.
Jeito Capital primarily invests in Europe and the United States, focusing on regions with robust healthcare ecosystems and opportunities for biopharmaceutical innovation.
The application process involves submitting a pitch through their website or via email. Founders should ensure that their proposals are well-structured and highlight the unique aspects of their innovations.
Jeito Capital actively engages with its portfolio companies, providing not only financial support but also strategic guidance and access to their extensive network in the healthcare sector to help accelerate growth.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.